Last reviewed · How we verify
NCT03630055: CAPITAL-RAPTOR
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
Phase 3 trial testing Rivaroxaban 15 MG Oral Tablet [Xarelto] in Radial Artery Occlusion in 1,800 participants. Currently enrolling.
30 December 2025
Quick facts
| Lead sponsor | Ottawa Heart Institute Research Corporation |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 1,800 |
| Start date | 3 October 2018 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 3 locations across Canada, United States |
Drugs / interventions tested
- Rivaroxaban 15 MG Oral Tablet [Xarelto]
Conditions studied
- Radial Artery Occlusion — all drugs for Radial Artery Occlusion →
Sponsor
Ottawa Heart Institute Research Corporation
Who can join
18 and older, any sex, with Radial Artery Occlusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in \~5% of patients which prohibits the use of the radial artery in the future. There is evidence to support the use of intraprocedural anticoagulation to mitigate the risk of radial artery occlusion however the role of post-procedural anticoagulation has not been previously evaluated. Rivaroxaban is a direct oral anticoagulant (DOAC) with a safety profile superior to that of vitamin K antagonists. Given the safety profile, ease of use, and feasibility of DOAC therapy, our study will endeavor to evaluate the use of rivaroxaban 15mg orally once daily for 7 days after transradial access and the impact this has on the rate of radial artery occlusion.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Prevention of radial artery occlusion with rivaroxaban after trans-radial access coronary procedures: The RIVARAD multicentric randomized trial.
Hammami R, Abid S, Jihen J, Triki Z, et al · · 2023 · cited 4× · PMID 37153470 · DOI 10.3389/fcvm.2023.1160459 -
Rationale and Design of the Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion Trial (CAPITAL-RAPTOR).
Di Santo P, Abdel-Razek O, Jung R, Parlow S, et al · · 2023 · cited 2× · PMID 37173116 · DOI 10.1136/bmjopen-2022-070720
Verify or expand the search:
- PubMed search for NCT03630055
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Radial Artery Occlusion
Currently open trials in the same condition.
- NCT06812455 — Effect of RIVAroxaban in Radial Artery Occlusion Treatment After Cardiac Catheterization · Phase 4 · recruiting
- NCT04933136 — Radial Artery Occlusion and Dual Artery Hemostasis After Transradial Approach. · recruiting
Other Ottawa Heart Institute Research Corporation trials
Trials by the same sponsor.
- NCT06907251 — Dapagliflozin for Long COVID Syndrome · Phase 3 · not yet recruiting
- NCT07002450 — Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Departm · NA · recruiting
- NCT06832085 — Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation · Phase 4 · recruiting
- NCT06556667 — MAX - SHOCK Clinical Trial · NA · recruiting
- NCT06816888 — Impact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03630055 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ottawa Heart Institute Research Corporation
- Last refreshed: 15 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03630055.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing